Please ensure Javascript is enabled for purposes of website accessibility

Why Albireo Pharma Stock Is Skyrocketing Today

By Prosper Junior Bakiny – Sep 8, 2020 at 12:34PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company reported positive data from a clinical trial.

What happened?

Shares of Albireo Pharma (ALBO -3.15%) are up by 41.4% as of 11:49 a.m. EDT on Tuesday, after soaring by as much as 79% earlier today. These gains are a result of the biopharmaceutical company reporting positive data from a phase 3 clinical trial for odevixibat, one of its lead pipeline candidates. The study investigated the safety and efficacy of odevixibat as a treatment for progressive familial intrahepatic cholestasis (PFIC). 

So what

PFIC is a rare genetic disease; patients with this condition have difficulty draining bile, a digestive fluid in the liver. The buildup of bile in the liver leads to symptoms such as pruritus (intense itching). There are several forms of PFIC, but Albireo Pharma's phase 3 study focused on PFIC1 and PFIC2. During the trial, odevixibat "reduced serum bile acid responses and improved pruritus assessments," thereby meeting its primary endpoint.

Doctor giving a thumbs up.

Image source: Getty Images.

The medicine was also well tolerated and even showed a safety profile comparable to that of a placebo. Said Richard Thompson, principal investigator of the study: "These data demonstrate that odevixibat reduced serum bile acids and improved pruritus in patients with PFIC. Coupled with the favorable safety and tolerability profile odevixibat exhibited, these data underscore the potential to improve upon the current standard of care, which typically consists of off-label medications or invasive surgeries including transplant."

Now what

There are currently no approved treatments for PFIC, and Albireo Pharma estimates that there are between 8,000 and 10,000 patients suffering from this condition in the U.S. and Europe. And considering the results the healthcare company released today, it seems likely that odevixibat will become the first approved drug for PFIC. Given those factors, it isn't surprising that enthusiastic investors are bidding up shares of Albireo Pharma today. 

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Albireo Pharma, Inc. Stock Quote
Albireo Pharma, Inc.
$18.75 (-3.15%) $0.61

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.